Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial

The Lancet Infectious Diseases · Elsevier

Аннотация

Publication date: October 2026 Source: The Lancet Infectious Diseases, Volume 26, Issue 10 Author(s): Frank Bähner, Saul N Faust, Leela R L Davies, Olga Blokhina, Donald M Brandon, William B Smith, Vengalil Krishna K Chatterjee, Hana Hassanin, Tara M Babu, Adam Zuiani, Susanne Steinhauser, Asaf Poran, Claire Brittain, Eric Mucker, Jay W Hooper, Robbert G van der Most, Pedro L Alonso, Özlem Türeci, Federico J Mensa, Uğur Şahin

Читать у издателя →

Похожие статьи